Lonza Group AG (LONN.SW)
Swiss · CHF · Healthcare · Diagnostics & Research
CHF 630.00 (-0.76%) as of
Key statistics
- Market cap
- 44.00B
- P/E (TTM)
- 41.75
- Forward P/E
- 28.19
- EPS (TTM)
- 15.09
- Dividend yield
- 0.79%
- 52-week range
- 454.60 – 636.20
- Beta
- 0.81
- Revenue (TTM)
- 6.87B
- Profit margin
- -1.60%
- Analyst target
- CHF 696.61
- Volume
- 26.71k
About Lonza Group AG
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- Basel, Switzerland
- Employees
- 20,141
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.